Skip to main content
Explore URMC

menu

GvHD: A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)

Research Question:
Will taking ruxolitinib in combination with corticosteroids be a safe and effective treatment for people with acute Graft vs Host Disease (GvHD)?

Basic Study Information

Purpose:
This is an open-label Study which means that both you and your Study Doctor will know what Study Drug you are receiving. Eligible subjects will begin treatment at 5 mg ruxolitinib twice daily. This may be increased to 10 mg twice daily after 3 days depending on your blood tests.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02953678?term=INCB+18424-271&rank=1
Study Reference #: IBMT-17007

Lead Researcher (Principal Investigator)

Lead Researcher: Jane Liesveld, MD

Study Contact Information

Study Coordinator: Katherine Nedrow
Phone: (585) 275-9485
Email: Katherine_Nedrow@urmc.rochester.edu

Additional Study Details

Return to Search